Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_assertion type Assertion NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_head.
- NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_assertion description "[The concentration of thrombin-activatable fibrinolysis inhibitor was particularly higher in patients with small cell carcinoma compared to those with adenocarcinoma or squamous cell carcinoma, and in cancer patients that responded to chemotherapy compared to non-responders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_provenance.
- NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_assertion evidence source_evidence_literature NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_provenance.
- NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_assertion SIO_000772 15224354 NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_provenance.
- NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_assertion wasDerivedFrom befree-20140225 NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_provenance.
- NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_assertion wasGeneratedBy ECO_0000203 NP531870.RA78JjTHGHRdg3NEvdtfQGBK2fzLys0ZGtSkoMap-HlNk130_provenance.